ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • 2026 ACR/ARP PRSYM
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 077

Integrated Spatial Transcriptomics and Proteomics in Reveals Aberrant Lymphoid Networks in Pediatric Lupus Nephritis

Nicholas Hasle1, Robyn C. Reed2, Virginia Hoglund3, Rebecca Martin3, Mark Conner3 and Shaun Jackson4, 1Seattle Children's Hospital / University of Washington, Seattle, WA, 2Seattle Children's Hospital, 3Seattle Children's Research Institute, 4Seattle Children's Research Institute, Seattle, WA

Meeting: 2026 Pediatric Rheumatology Symposium

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Thursday, March 19, 2026

Title: Abstracts: Systemic Lupus Erythematosus

Session Time: 5:29PM-5:34PM

Background/Purpose: Childhood lupus nephritis (cLN) is a life-threatening manifestation of systemic lupus erythematosus and frequently demonstrates incomplete response to standard immunosuppression. The mechanisms driving persistent inflammation remain poorly understood, in part because existing spatial profiling platforms measure RNA, rather than protein expression, of 1,000 or fewer genes. The purpose of this study was to leverage a high-plex, integrated spatial transcriptomics and proteomics platform to map 6,000 genes and 64 proteins across hundreds of thousands of cells from pediatric cLN biopsies. By comparing diseased kidneys to healthy tonsillar immune architecture, we aimed to identify aberrant lymphocyte developmental states and immune circuits that may represent novel therapeutic targets.

Methods: Patients with biopsy-confirmed class III or IV cLN, and a patient who received a nephrectomy for a non-inflammatory indication, were enrolled in a no-contact clinical study approved by the Seattle Children’s Hospital Institutional Review Board (IRB). Subsequently, previous biopsies obtained for clinical diagnostic purposes at or near diagnosis were subject to the CosMx Human Multiomics platform (Bruker). De-identified tonsillar tissue obtained as part of routine clinical care was subject to the same platform. Cell profiles were subject to Insitutype, a Bayesian method for identifying cell types, using the Kidney Precision Medicine Project (KPMP) v1 reference cell types; or subject to unsupervised clustering via PCA and UMAP using the transcriptional data only. Differential gene testing and spatial relationship analyses were performed for lymphocyte cell subclusters that were shared between tonsillar and cLN tissues.

Results: Supervised cell identification of 47,470 kidney cells revealed a large increase in the number of lymphocytes observed in cLN (13.1% of all cells profiled), compared to the non-inflammatory kidney control (0.5% of all cells profiled). Approximately 33% of these highly abundant lupus nephritis lymphocytes were mapped to clusters also observed in the healthy tonsillar tissue. Comparing “tonsillar-like” to “non-tonsillar” B lymphocytes revealed differential gene patterns associated with antigen presentation, specifically upregulation of MHC molecules and CD37, which are critical for T-B cell interactions in germinal centers. Spatial relationships between cell subclusters is ongoing as of the submission of this abstract.

Conclusion: The striking similarities between tonsillar and lupus nephritis lymphocytes suggests that there is aberrant lymph-node like differentiation of B and T cells within the interstitial space in patients with cLN. This is congruent with past reports of tertiary lymphoid structures being observed in autoimmune diseases. The maturation of B and T cells in the kidney suggests that at least some autoreactive T and B cells are continuously generated in situ, rather than being generated solely in dedicated secondary lymphoid follicles. This in situ autoreactive lymphocyte development may be a keystone in the pathogenesis of lupus nephritis, as evidenced by the recent success of deep CD19-directed B cell-depleting therapies.

UMAP of all cells from patients with lupus nephritis, control patients, and healthy tonsillar tissueSupporting image 1Cells obtained using needle kidney biopsy are colored according to their cell type, as determined using Insitutype, a Bayesian algorithm for supervised cell type identification, using the Kidney Precision Medicine Partnership (KPMP) reference dataset.


Disclosures: N. Hasle: Bristol-Myers Squibb(BMS), 11, Immunome, 11; R. Reed: None; V. Hoglund: None; R. Martin: Bristol-Myers Squibb(BMS), 11, Merck/MSD, 11; M. Conner: None; S. Jackson: Amgen, 2, Bristol-Myers Squibb(BMS), 2, IgM Biosciences, 2, Merck/MSD, 2, Sail BioMedicines, 2.

To cite this abstract in AMA style:

Hasle N, Reed R, Hoglund V, Martin R, Conner M, Jackson S. Integrated Spatial Transcriptomics and Proteomics in Reveals Aberrant Lymphoid Networks in Pediatric Lupus Nephritis [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 3). https://acrabstracts.org/abstract/integrated-spatial-transcriptomics-and-proteomics-in-reveals-aberrant-lymphoid-networks-in-pediatric-lupus-nephritis/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to 2026 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/integrated-spatial-transcriptomics-and-proteomics-in-reveals-aberrant-lymphoid-networks-in-pediatric-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology